Skip to content
Screener

Total Revenue at other companies

Pfizer logo
PfizerPFE
$15.03B+2.6%
Cardinal Health logo
Cardinal HealthCAH
$60.94B+11.0%
McKesson logo
McKessonMCK
$105.38B+7.7%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$266.04M+25.9%
Cencora logo
CencoraCOR
$84.75B+5.1%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$1.07B+19.1%

Segments

By product

See full
Subtotal dosage forms$482.3M+11.8%
Oral solid$175.17M-1.7%
Subtotal therapeutic classes$149.3M+17.1%
Central nervous system$95.34M+14.3%
Distribution$86.93M-12.8%
Other dosage forms$81.59M+19.7%

By segment

See full
Affordable Medicines$489.91M
AvKARE$156.99M-3.7%

Other financials

Income statement

See full
Gross profit$334.5M+16.9%
Operating income$129.8M+16.5%
Net income$57.7M+157%
EPS (diluted)$0.18+157%

Balance sheet

See full
Cash & equivalents$127.6M+78.4%
Total debt$2.6B+18.0%
Total equity$33.0M+129%
Total assets$3.8B+10.3%

Cash flow

See full
Operating cash flow-$21.2M-125%
CapEx$30.7M+34.5%
Free cash flow-$51.9M-185%

Valuation

See full
Market cap$5.89B+134%
Enterprise value$8.34B+80.1%
P/E37.5×-710×
P/S1.9×+1.0×

Profitability

See full
Gross margin39.3%+1.7pp
Operating margin14.6%+1.4pp
Net margin5%+4.9pp
FCF margin4.1%-5.8pp

Returns & leverage

See full
Return on equity-52.8%-12.7pp
Debt / equity77.8×
Current ratio2.2×+0.8×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001723128-26-000031
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Net revenue$796,197$724,508$1,518,716$1,419,928
Cost of goods sold461,689438,255864,095877,784
Gross profit334,508286,253654,621542,144
Selling, general and administrative148,722124,266287,582242,554
Research and development39,01747,96477,40088,004
Intellectual property legal development expenses2,0872,0173,6293,784
Acquisition costs7,60012,753
Restructuring and other charges5541,0241,2041,595

Item 1. Financial Statements (Unaudited)

FAQ

What is Amneal Pharmaceuticals, Inc.'s total revenue?
Amneal Pharmaceuticals, Inc. (AMRX) reported total revenue of $796.2M in Q2 2026.
How has Amneal Pharmaceuticals, Inc.'s total revenue changed year-over-year?
Amneal Pharmaceuticals, Inc.'s total revenue increased by 9.9% year-over-year, from $724.51M to $796.2M.
What is the long-term trend for Amneal Pharmaceuticals, Inc.'s total revenue?
Over 4 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s total revenue has grown at a 9.6% compound annual growth rate (CAGR), from $2.09B to $3.02B.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.

Ask your AI about Amneal Pharmaceuticals, Inc.'s total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude